These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers. Vishnu P; Moreno Vanegas Y; Wadei HM; Rivera CE BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29954763 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients. Ahmed S; Ahmed E; Naqvi R; Qureshi S J Pak Med Assoc; 2012 Dec; 62(12):1326-9. PubMed ID: 23866484 [TBL] [Abstract][Full Text] [Related]
6. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Klaassen RJ; van Gelder T; Rischen-Vos J; Deinum J; Man in't Veld AJ; Weimar W Transplantation; 1997 Sep; 64(5):780-2. PubMed ID: 9311722 [TBL] [Abstract][Full Text] [Related]
7. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535 [TBL] [Abstract][Full Text] [Related]
8. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft. Pisani F; Tisone G; Alciati E; Vennarecci G; Pieragostini E; Casciani CU Transplant Proc; 1994 Oct; 26(5):2602-3. PubMed ID: 7940809 [No Abstract] [Full Text] [Related]
9. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. Julian BA; Brantley RR; Barker CV; Stopka T; Gaston RS; Curtis JJ; Lee JY; Prchal JT J Am Soc Nephrol; 1998 Jun; 9(6):1104-8. PubMed ID: 9621296 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF. Stoll ML; Gauthier BG; Vergara M; Ramek J; Frank R; Trachtman H Pediatr Nephrol; 2004 Jan; 19(1):120-1. PubMed ID: 14634866 [No Abstract] [Full Text] [Related]
12. Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients. Kupin W; Venkat KK; Goggins M; Abouljoud M; Escobar F; Mozes M Transplant Proc; 1997; 29(1-2):207-8. PubMed ID: 9122965 [No Abstract] [Full Text] [Related]
17. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis. Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608 [TBL] [Abstract][Full Text] [Related]
18. Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition. Mulhern JG; Lipkowitz GS; Braden GL; Madden RL; O'Shea MH; Harvilchuck H; Guarnera JM; Germain MJ Am J Nephrol; 1995; 15(4):318-22. PubMed ID: 7573190 [TBL] [Abstract][Full Text] [Related]
19. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Hortal L; Fernández A; Vega N; RodrÃguez JC; Losada A; Lorenzo M; Plaza C; Palop L Transplant Proc; 1998 Aug; 30(5):2127-8. PubMed ID: 9723415 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]